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demyelinating white matter lesions. Furthermore, the 
expression patterns of Nrf2-induced genes differed between 
the white matter and cortical gray matter. Our study shows 
that in the MS brain, Nrf2 expression varies in different cell 
types and is associated with active demyelination in the 
lesions.
Keywords Multiple sclerosis · Nrf2 · Oxidative stress · 
Demyelination · Neurodegeneration · Fumarate · BG12
Abbreviations
MS  Multiple sclerosis
RRMS  Relapsing–remitting MS
PPMS  Primary progressive MS
SPMS  Secondary progressive MS
NWM  Normal white matter
NAWM  Normal-appearing white matter
PPWM  Periplaque white matter
Nrf2  Nuclear factor (erythroid-derived 2)-like 2
HO-1  Heme oxygenase 1
AIF  Apoptosis-inducing factor
CAII  Carbonic anhydrase II
GFAP  Glial fibrillary acidic protein
KLF-9  Kruppel-like factor 9
Introduction
Recent studies suggest a major role of oxidative injury in 
the pathogenesis of demyelination and neurodegeneration 
in multiple sclerosis (MS). This view is based on the pres-
ence of oxidized lipids, proteins and DNA in MS lesions [4, 
43], in particular in oligodendrocytes within active lesions 
[21] and in neurons within areas of severe active corti-
cal demyelination and neurodegeneration [15]. Oxidative 
Abstract Oxidative injury appears to play a major role in 
the propagation of demyelination and neurodegeneration in 
multiple sclerosis (MS). It has been suggested that endog-
enous anti-oxidant defense mechanisms within MS lesions 
are insufficient to prevent spreading of damage. Thus, cur-
rent therapeutic approaches (e.g., fumarate treatment) tar-
get to up-regulate the expression of a key regulator of anti-
oxidative defense, the transcription factor nuclear factor 
(erythroid-derived 2)-like 2 (Nrf2). In this study, we show 
that Nrf2 is already strongly up-regulated in active MS 
lesions. Nuclear Nrf2 expression was particularly observed 
in oligodendrocytes and its functional activity is indicated 
by the expression of one of its downstream targets (heme 
oxygenase 1) in the same cells. In contrast, only a minor 
number of Nrf2-positive neurons were detected, even in 
highly inflammatory cortical lesions presenting with exten-
sive oxidative injury. Overall, the most pronounced Nrf2 
expression was found in degenerating cells, which showed 
signs of apoptotic or necrotic cell death. Via whole-genome 
microarray analyses of MS lesions, we observed a differ-
ential expression of numerous Nrf2-responsive genes, also 
involved in the defense against oxidative stress, predomi-
nantly in areas of initial myelin destruction within actively 
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injury is associated with the presence of activated micro-
glia-expressing enzymes involved in oxygen radical pro-
duction such as NADPH oxidases [14, 15] and myeloper-
oxidase [20]. Additionally, oxidative tissue damage may be 
aggravated via the Haber–Weiss Fenton reactions catalyzed 
by redox-active iron, which has been shown to be present in 
and around a subset of classical active and slowly expand-
ing lesions, respectively [22]. Furthermore, mitochondrial 
injury, which is prominent within MS lesions and the nor-
mal-appearing cortex [8, 29], may be induced by oxidative 
injury but can also amplify oxidative stress [32]. The data 
suggest that in early MS, oxidative injury may be driven by 
inflammation and radical production in activated microglia 
and amplified in the progressive stage of MS by age- and 
disease burden-related additional mechanisms [27, 30].
A prominent defense mechanism counteracting oxida-
tive stress is the induction of the transcription factor nuclear 
factor (erythroid-derived 2)-like 2 (Nrf2; encoded by the 
NFE2L2 gene), which triggers the expression of a variety 
of anti-oxidative defense molecules when translocated into 
the nucleus [9, 10]. Experimental autoimmune encephalo-
myelitis was more severe in Nrf2-deficient mice in com-
parison with wild-type littermates [24], and induction of 
Nrf2 expression by treatment with fumarate was protective 
in this animal model [28]. For these reasons and since the 
induction of endogenous anti-oxidant defense mechanisms 
might be insufficient in MS lesions, therapeutic trials test-
ing dimethyl fumarate for its neuroprotective effects have 
been initiated and in part already conducted in MS patients 
[16, 18, 37, 39]. So far, results show a reduction of relapses 
and magnetic resonance imaging (MRI) activity in patients 
with relapsing–remitting MS (RRMS), which was associ-
ated with a significant reduction of sustained disability pro-
gression in one of the two phase III trials.
Nrf2 has been described to be consistently up-regulated 
in multiple sclerosis plaques, but it was only detected in 
astrocytes and macrophages [41] and in some spinal cord 
neurons [28]. It has not been detected in oligodendro-
cytes so far, which are the prime target for oxidative dam-
age within demyelinating lesions. In our present study, we 
report a high nuclear Nrf2 reactivity in oligodendrocytes 
in actively demyelinating lesions in patients with acute, 
relapsing as well as progressive disease. Most extensive 
Nrf2 expression was present in degenerating cells. Our 
observations raise doubts that further stimulation of Nrf2 
by fumarate-induced cell stress protects oligodendrocytes 
in active lesions.
Materials and methods
The study was performed on formalin-fixed paraffin-
embedded (FFPE) autopsy brain tissue derived from 28 
controls without neurological disease and 23 MS cases 
(Table 1). The MS cohort included 6 acute MS (AMS) 
cases defined by a clinical course leading to death within 
12 months after disease onset. One patient died during dis-
ease exacerbation in the RRMS stage. Nine patients pre-
sented with secondary progressive MS (SPMS) and seven 
with primary progressive MS (PPMS). The control cases 
included patients without neurological disease and neuro-
pathologically detectable lesions in the central nervous sys-
tem. In addition we included 2 brain biopsies of progres-
sive multifocal leukoencephalopathy (PML) patients, who 
were treated daily with 4 (patient 1) and 5 (patient 2) tab-
lets of Fumaderm (120 mg dimethyl fumarate and 95 mg 
monomethyl fumarate) until the last day before diagnostic 
brain biopsy. For control reasons, we included 2 brain biop-
sies from PML patients without fumarate therapy (Table 1). 
To determine the effect of systemic inflammation on Nrf2 
expression in the brain, the control cohort also included 
patients, who died under septic conditions. Clinical and 
pathological information on the patients is summarized in 
Table 1. This study was approved by the ethics committee 
of the Medical University of Vienna (EK No. 048/01/2014).
Neuropathology and immunohistochemistry
All disease and control autopsy cases underwent detailed 
neuropathological examination of multiple tissue blocks 
covering various brain regions. Lesion activity was evalu-
ated as previously described [17, 26]. Routine immuno-
histochemistry was performed on paraffin sections accord-
ing to established techniques [2, 25]. For a detailed list of 
primary antibodies, dilutions and respective pre-treatment 
of tissue sections see Table 2. For Nrf2 stainings, we used 
two different primary antibodies, which resulted in very 
similar staining patterns. However, in combination with 
FFPE tissue, the antibody from Abcam showed a bit higher 
degree of sensitivity and less background staining and was, 
thus, used for quantitative analysis of Nrf2 expression. 
Cells with nuclear DNA fragmentation were identified via 
TUNEL staining [19].
For fluorescent double and triple labeling of Nrf2 with 
cell type-specific markers and heme oxygenase 1, tissue 
sections were routinely dewaxed and rehydrated. After the 
respective antigen retrieval, primary antibodies for Nrf2 
and cell type-specific markers were applied simultaneously 
at 4 °C overnight. After washing with TBS, secondary anti-
body mixes consisting of biotinylated-anti-rabbit (Jackson 
ImmunoResearch, 1:2000) and anti-mouse, -rat, -sheep or 
-goat antibodies conjugated to Cy3 or Cy5 (Jackson Immu-
noResearch; 1:100) were applied simultaneously for 1 h at 
room temperature. Subsequently, the staining procedure 
was finished by incubation with streptavidin-Cy2 (Jack-
son ImmunoResearch; 1:100) for 1 h at room temperature. 
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Table 1  Clinical demographics
Case ID Disease 
course







MS 1 AMS 78 M 2 – No MSR
MS 2 AMS 34 F 4 – S MSR
MS 3 AMS 45 M 0.2 – S MSR
MS 4 AMS 69 F 2 – S MSR
MS 5 AMS 35 M 1.5 – S MSR
MS 6 AMS 45 M 1,5 – S MSR
MS 7 RRMS 40 F 120 – S UK
MS 8 SPMS 41 M 137 99 Mit, IFNβ, S CV
MS 9 SPMS 34 M 120 n.a. No UK
MS 10 SPMS 42 F 241 87 No UK
MS 11 SPMS 53 F 241 104 S P
MS 12 SPMS 62 F 144 n.a. S P
MS 13 SPMS 48 F 410 182 No UK
MS 14 SPMS 46 F 444 228 No CV
MS 15 SPMS 56 M 372 132 No CV
MS 16 SPMS 59 F 492 168 S CV
MS 17 PPMS 55 F 60 60 No PE
MS 18 PPMS 36 M 61 61 No PE
MS 19 PPMS 71 F 264 264 No PE
MS 20 PPMS 53 M 168 168 No CV
MS 21 PPMS 77 F 168 168 No CV
MS 22 PPMS 67 M 87 87 No CV
MS 23 PPMS 54 F 72 72 No CV
Control 1 Control 39 F – – –
Control 2 Control 36 F – – –
Control 3 Control 46 M – – –
Control 4 Control 45 F – – –
Control 5 Control 47 F – – –
Control 6 Control 29 F – – –
Control 7 Control 57 M – – –
Control 8 Control 42 F – – –
Control 9 Control 46 M – – –
Control 10 Control 72 M – – –
Control 11 Control 65 M – – –
Control 12 Control 67 M – – –
Control 13 Control 73 M – – –
Control 14 Control 71 F – – –
Control 15 Control 80 F – – –
Control 16 Control 84 F – – –
PML + fumarate 1 PML 77 M – – Fumarates for psoriasis Brain biopsy
PML + fumarate 2 PML 68 M – – Fumarates for psoriasis Brain biopsy
PML control 1 PML 60 M – – – Brain biopsy
PML control 2 PML 85 M – – – Brain biopsy
Septic control 1 Septic control 97 F – – –
Septic control 2 Septic control 37 M – – –
Septic control 3 Septic control 71 F – – –
Septic control 4 Septic control 45 M – – –
Septic control 5 Septic control 74 M – – –
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Fluorescent preparations were examined using a Leica SP2 
confocal laser scan microscope (Mannheim, Germany).
Quantitative analysis of Nrf2 expression and statistical 
evaluation
For quantitative analysis, all respective tissue slides were 
stained for Nrf2 at the same time. This allowed not only to 
separate cells with intense versus weak expression within 
different areas of a single section, but also between sections 
of different MS or control cases. The following regions of 
interest were analyzed in the white matter: In and around 
active white matter plaques defined by the presence of mac-
rophages with early myelin degradation products [5], we 
differentiated between the normal-appearing white matter 
(NAWM; at least 1 cm distant from the plaque edge), the 
periplaque white matter (PPWM; 0.2–0.5 mm distant from 
the plaque edge), areas of initial demyelination (prephago-
cytic area characterized by profound microglia activation, 
scattered macrophages with early myelin degradation prod-
ucts, myelin sheaths with initial stages of dissolution and 
oligodendrocyte apoptosis) [1, 26] and the demyelinated 
plaque center densely packed with macrophages containing 
early and late myelin degradation products [5]. In slowly 
expanding (smoldering) plaques, NAWM and PPWM were 
defined similarly as in active plaques. The zone of active 
demyelination was defined by the presence of numerous 
activated microglia and scattered macrophages with early 
myelin degradation products. Additionally, the inactive 
plaque center was analyzed as well. Inactive lesions were 
defined by their sharp plaque edge, the absence of a rim 
containing activated microglia and the lack of macrophages 
Table 1  continued
Case ID Disease 
course







Septic control 6 Septic control 51 F – – –
Septic control 7 Septic control 70 M – – –
Septic control 8 Septic control 71 M – – –
Septic control 9 Septic control 95 F – – –
Septic control 10 Septic control 42 F – – –
Septic control 11 Septic control 89 F – – –
Septic control 12 Septic control 79 F – – –
MS multiple sclerosis, AMS acute multiple sclerosis, RRMS relapsing–remitting multiple sclerosis, SPMS secondary progressive multiple sclero-
sis, PPMS primary progressive multiple sclerosis, F female, M male, n.a. not available
MS-related treatment (last month before death): No no immunosuppressive or immunomodulatory therapy; S steroids, Mitox mitoxantrone; IFN-
β β-interferon
Cause of death: MSR directly MS related, CV cardiovascular, PE pulmonary embolism, P pneumonia, UK unknown
Table 2  Primary antibodies and antigen retrieval
mAB monoclonal antibody, pAB polyclonal antibody, C citrate buffer pH 6, E ethylenediaminetetraacetic acid buffer pH 9.0
Primary antibody Antibody type Target Source Staining
CA II Sheep (pAB) Carbonic anhydrase II PC076; BindingSite 1:1500; E
CD68 Mouse (mAB) Cluster of differentiation 68 M0814; Dako 1:100; E
E06 Mouse (mAB) Oxidized phospholipids [34] 10 µg/ml; none
GFAP Mouse (mAB) Glial fibrillary acid protein 0410080; ThermoSc 1:200; E
HLA-DP, DQ, DR Mouse (mAB) Human leukocyte antigen M0775; Dako 1:100; E
HO-1 Rabbit (pAB) Heme oxygenase-1 ab13243; Abcam 1:2000; CSA; C
KEAP1 Mouse (mAb) Kelch-like ECH-associated protein 1 NBP2-03319, Novus Biologicals 1:250; E
MAG Mouse (mAB) Myelin-associated glycoprotein ab89780; Abcam 1:1000; E
MAP 2 Mouse (mAB) Microtubule-associated protein 2 M4403; Sigma 1:100; E
Nrf2 Rabbit (mAB) Nuclear factor (erythroid-derived 2)-like 2 ab62352; Abcam 1:100; E
Nrf2 Rabbit (pAB) Nuclear factor (erythroid-derived 2)-like 2 C-20; Santa Cruz 1:500; C
p22phox Rabbit (pAB) NADPH oxidase Sc-20781; Santa Cruz 1:100; C
PLP Mouse (mAB) Proteolipid protein MCA8394; AbD Serotec 1:1000; E
Tppp/p25 Rat (pAB) Tubulin polymerization-promoting protein [23] 1:100; E
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with myelin degradation products. In addition, we quanti-
fied neurons with nuclear Nrf2 expression in the cerebral 
cortex of MS patients with progressive disease and pres-
ence of cortical lesions, control cases and in biopsies from 
patients with progressive multifocal leukoencephalopathy 
with or without treatment with fumarates. Nrf2-positive 
nuclei were counted at the microscope using the 40× 
objective with a counting grid in one of the ocular lenses. 
In the white matter, 10 visual fields of 0.25 mm2 were 
counted, thus the values shown in the figures represent 
cells per 2.5 mm2. Separate counts are provided for differ-
ent regions of interest in white matter lesions. Analysis of 
Nrf2-positive neurons was performed in the same way as 
described before for white matter lesions. However, since 
we did not see differences in the presence of Nrf2-positive 
neurons within and outside cortical lesions in MS, the val-
ues were pooled per case.
Statistical analysis was performed with nonparamet-
ric tests. Statistical difference between two groups was 
assessed by Mann–Whitney U test. For the comparison of 
multiple groups with controls, the Kruskal–Wallis test was 
used, followed by pairwise Mann–Whitney U tests and 
Bonferroni–Holm correction. A P value smaller or equal to 
0.05 was considered as statistically significant. Data were 
presented as scatter plots showing all actual data points as 
well as the median of each group.
Whole‑genome microarrays
For gene expression analysis of Nrf2-responsive genes in 
active white matter and cortical lesions, we used whole-
genome microarray datasets already created in previous 
studies [14, 15, 22]. For microarray analysis of active 
white matter lesions, four cases with acute MS (MS2, 
MS3, MS4, MS6) and four normal controls were chosen 
[14, 22]. From the MS material, three different regions of 
interest were microdissected: (a) NAWM (at least 0.5 mm 
apart from the lesion edge); (b) zone of initial demyeli-
nation showing partial demyelination and tissue infiltra-
tion with macrophages containing early myelin degrada-
tion products; and (c) demyelinated plaque centers, which 
were still densely packed with macrophages containing 
late myelin degradation products (late active lesions; [5]). 
For microarray analysis of cortical lesions, three patients 
with secondary progressive MS (MS8, MS10, MS13), 
who showed active demyelination in the cerebral cortex, 
and three controls without neurological disease and brain 
lesions were chosen [15]. At least the outer four cortical 
layers of lesions with subpial demyelination or all corti-
cal layers were microdissected from MS or control tissue, 
respectively. The cortical lesion sample contained mate-
rial from one MS patient (MS10, previously described as 
MS1 in [15]), who presented with epileptic seizures prior 
to death and showed highly inflammatory active subpial 
lesions in many cortical regions. Data from this patient 
were additionally analyzed separately since they derived 
from lesions with an extreme degree of active inflam-
mation, microglia activation and oxidative injury. RNA 
isolation, amplification and microarray technology have 
been described in detail in previous studies [14, 15]. All 
microarray datasets have been deposited at NCBI’s Gene 
Expression Omnibus (GEO accession numbers GSE32915 
and GSE32645).
Results
Nuclear Nrf2 expression is increased around active 
demyelinating MS lesions
In the normal white matter (NWM) of controls and the 
NAWM of MS patients, only few cells were positive for 
Nrf2 (Fig. 1a–g). Nrf2 reactivity was found either in the 
cytoplasm or in addition in the cell nucleus. For quan-
tification, only cells with a nuclear Nrf2 reactivity were 
counted. In the PPWM, a clear nuclear accumulation of 
Nrf2 was present gradiently increasing towards the zone 
of initial demyelination (prephagocytic lesion area [1]) at 
the active lesion edge (Fig. 1c, f, h). Nrf2 immunoreactiv-
ity was mainly detected in small cells with oligodendrocyte 
morphology and in lower incidence in cells with astrocyte 
or macrophage phenotype. In the demyelinated part of the 
lesions [5], in which myelin was completely destroyed and 
myelin fragments were present within phagocytes (defined 
as late active lesion area; Fig. 2), the staining for Nrf2 
was low and comparable to the extent seen in the NAWM 
(Fig. 1a–f, i). This expression pattern was also reflected 
in quantitative analyses of Nrf2-immunoreactive cells 
(Fig. 2a, b). The Nrf2 expression patterns were similar in 
classical active lesions in acute MS and RRMS (Fig. 2a) 
and smoldering lesions in SPMS and PPMS (Fig. 2b). 
However, the absolute numbers of cells with a nuclear Nrf2 
accumulation was higher in acute MS and RRMS cases 
compared with PPMS/SPMS cases.
Within the cytoplasm, Nrf2 is bound to Kelch-like ECH-
associated protein 1 (KEAP1), which facilitates its degra-
dation and Nrf2 becomes active after dissociation [10]. We 
found KEAP1 reactivity within neurons and different glia 
cells within the white and gray matter of MS patients and 
control cases. KEAP1 immunoreactivity was increased at 
the edge of active lesions, but this reactivity was restricted 
to the cytoplasm and in contrast to Nrf2 not seen in the 
nucleus (Suppl. Fig. 1), where active Nrf2 acts as a tran-
scription factor.
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Oligodendrocytes are the dominant cells showing 
nuclear Nrf2 reactivity in active MS lesions
To determine which cell types expressed Nrf2 in MS 
lesions, we performed immunohistochemical double and 
triple stainings using confocal laser microscopy. Nrf2 
expression was detected within MS lesions in oligoden-
drocytes (Figs. 1j, k, 2c), astrocytes (Fig. 1l), macrophages 
(Fig. 1m) and neurons (Fig. 4c, d). There were, however, 
quantitative differences in the numbers of positive oligo-
dendrocytes, astrocytes and macrophages between different 
lesion stages. At the edge of active demyelinating lesions, 
the vast majority of Nrf2-positive cells showed morpho-
logical features of oligodendrocytes (Fig. 2c) and most of 
these cells were double stained with CAII (Fig. 1j). A lower 
number of cells co-stained with GFAP (astrocytes; Fig. 1l) 
or CD68 [macrophages/microglia (Fig. 1m)]. The latter 
cells were mainly seen in the demyelinated portion of late 
active lesions, which showed oligodendrocyte loss and the 
presence of macrophages containing myelin degradation 
products (Fig. 2c).
Most intense Nrf2 reactivity is found in degenerating 
cells with nuclear translocation of apoptosis‑inducing 
factor (AIF)
At the active lesion edge, an additional cell population with 
a very intense Nrf2 expression, which no longer allowed 
the differentiation between nucleus and cytoplasm, was 
present (Fig. 1k). These cells represented in average 4.6 % 
of cells with nuclear Nrf2 reactivity in active lesions of 
acute MS and 2.5 % in expanding lesions in progressive 
MS. Cell size and shape were suggestive of oligodendro-
cytes, however, these cells did neither express any markers 
for oligodendrocytes nor for astrocytes, microglia or neu-
rons (Fig. 1h, k). Loss of cellular marker protein expression 
is typically seen in conditions of acute apoptotic or necrotic 
cell death. Cell death in oligodendrocytes in MS lesions is 
associated with the liberation of apoptosis-inducing fac-
tor (AIF) from mitochondria and its translocation into the 
nucleus [44] as well as with nuclear DNA fragmentation in 
the absence of caspase 3 activation. Via fluorescent double 
labeling, we detected a cytoplasmic and nuclear co-locali-
zation of Nrf2 and AIF in these highly Nrf2-positive cells 
(Fig. 1p–s). Furthermore, fragmented nuclear DNA was 
occasionally seen in highly Nrf2-positive cells by TUNEL 
staining (Fig. 1t, u).
Functional activity of Nrf2 is suggested due to a 
differential expression of target genes
To determine the activity of Nrf2, we examined the expres-
sion of Nrf2-responsive genes (respective references for 
each gene are given in Supplementary Table 1). In the 
white matter, the most pronounced changes in gene expres-
sion were seen in microdissected areas of initial lesions. 
Thus, up-regulation of Nrf2 responsive genes was seen in 
exactly the same lesion area, which also showed the most 
profound expression and nuclear translocation of Nrf2 
by immunohistochemistry (Figs. 2, 3). As summarized in 
Supplementary Table 1, we found three different response 
patterns, two of them further depicted in Fig. 3. The first 
group of genes (Group 1) showed a low basal expression 
in the NWM of controls, but was up-regulated in active 
white matter lesions in particular in the zones of initial 
Fig. 1  Nrf2 expression in multiple sclerosis white matter lesions. a–c 
Active demyelinating lesion of an acute MS case (case MS 5). a A 
decreased Luxol fast blue-periodic acid Schiff myelin staining indi-
cates sites of ongoing demyelination. The insets show myelin deg-
radation products in the Luxol fast blue staining (blue) and the PLP 
staining (brown). b In the same area, abundant activated microglia are 
stained for p22phox (NADPH oxidases). c The Nrf2 staining displays 
an increased nuclear expression in oligodendrocyte-like cells around 
the active lesion edge decreasing towards both the NAWM and the 
lesion center. Smoldering active demyelinating lesion of a PPMS 
case (MS 21). d Sites of demyelination are detectable by a loss of 
PLP staining. The inset shows myelin degradation products. e The 
p22phox staining illustrates abundant activated microglia around the 
lesion. f At the active lesion edge, an increase in nuclear Nrf2 accu-
mulation can be observed, while Nrf2 expression decreases towards 
the NAWM and lesion center. Higher magnifications of NAWM (g), 
active lesion edge (h) and lesion center (i) highlight the differences 
in Nrf2 expression between the different zones in more detail (case 
MS 22). Within the active lesion edge (h) abundant cells with oligo-
dendrocyte morphology with high nuclear accumulation of Nrf2 are 
present. j Fluorescent triple labeling of Nrf2 (green), CA II (red) 
and GFAP (blue) shows oligodendrocytes with cytoplasmic (left) 
and nuclear accumulation (right) of Nrf2 around the active lesion 
edge. k The same fluorescent labeling as in (j) illustrates a cell with 
extremely high nuclear Nrf2 accumulation, which has lost cellular 
marker protein expression (arrow). Additionally, a cell with cyto-
plasmic Nrf2 accumulation and only moderate expression of CAII 
(arrowhead) is depicted. The red-stained cell on the right represents 
a normal oligodendrocyte with strong CAII reactivity and only minor 
granular Nrf2 reactivity. l Fluorescent double labeling of Nrf2 (green) 
and GFAP (red) shows an astrocyte with cytoplasmic and nuclear 
Nrf2 accumulation. m Fluorescent double labeling of Nrf2 (green) 
and CD68 (red) shows cytoplasmic and nuclear Nrf2 reactivity in 
a macrophage. n Double staining of Nrf2 (red) and HO1 (green) 
reveals expression of both antigens in the same cell. o Triple staining 
of Nrf2 (blue), CaII (red) and HO-1 (green) shows coexpression of 
all markers in the right-hand cell, HO-1 expression in another CAII-
positive oligodendrocyte (middle cell) and a single CAII-positive 
oligodendrocyte (left cell). p–s AIF staining (red) in relation to Nrf2 
expression (green). p and q depict serial images of a cell, which is 
negative for Nrf2 but presents with a punctate mitochondrial staining 
for AIF. r and s show two cells with massive cytoplasmic and nuclear 
Nrf2 staining (r). In these cells, AIF is in part released from mito-
chondria into the cytoplasm and has translocated into the nucleus 
(s). t, u Double staining for Nrf2 and TUNEL depict cells with 
strong cytoplasmic and nuclear Nrf2 expression (red), which show 
nuclear DNA fragmentation (black) in an early (t; case MS 21) and 
late stage (u) of cell death (case MS 1). Scale bars a–f = 300 µm; 
g–i = 100 µm; j–u = 20 µm
◂
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demyelination. The second pattern (Group 2) included 
genes, which were already expressed in high levels in the 
NWM of controls. In this group, about half of the genes 
showed an increased expression in the area of initial demy-
elination, while a lower fraction was unchanged or down-
regulated. Finally, a number of genes (Supplementary 
Table 1; Group 3) showed a very low basal expression 
in the NWM of controls and did not reveal any dynamic 
expression changes in MS lesions. They were either not 
expressed within the central nervous system at all, or were 
for technical reasons false negative in the microarrays 
derived from paraffin material as already extensively dis-
cussed before [14, 15].
Heme oxygenase (HO-1; encoded by the HMOX gene), 
a downstream target of Nrf2 [11], was one of the genes, 
which was up-regulated in initial white matter lesions 
(Fig. 3b). It cleaves heme into CO, ferrous iron and bili-
verdin, which is subsequently converted to bilirubin, a 
potent anti-oxidant. Via immunohistochemistry, we found 
an expression profile of the HO-1 protein similar to that 
of Nrf2. Most of the cells expressing HO-1 morphologi-
cally resembled oligodendrocytes and expressed the oli-
godendrocyte marker CAII (Figs. 1n, o, 4k). Quantitative 
analysis of fluorescent double labeling of HO-1 and Nrf2 
showed a co-localization of Nrf2 and HO-1 within 68 % 
of the immunostained cells, whereas 17 and 15 % were 
Fig. 2  Nrf2 expression in MS lesions and controls. a, b Nrf2 expres-
sion in the normal white matter of controls (NWM), in the normal-
appearing white matter of MS patients (NAWM), in the periplaque 
white matter (PPWM), at the active lesion edge and in the late active 
or inactive lesion center. Nrf2 expression is significantly increased 
in the PPWM and at the active edge of active demyelinating lesions 
in patients with acute MS and RRMS (a) and in slowly expanding 
lesions in patients with PPMS and SPMS (b), in comparison with 
normal white matter of controls. c The average numbers of Nrf2-
positive oligodendrocytes, astrocytes and macrophages at the edge of 
active lesions and in the demyelinated (late active) lesion center are 
depicted. d In comparison with the white matter of unaffected con-
trol patients, Nrf2 expression is increased in control patients with 
concomitant microinfarcts and in control patients without patho-
logical alteration in the brain or spinal cord, who died under septic 
conditions. Scatter plots depict all actual data points (black dots) as 
well as the median of each group (gray bars) *P < 0.05; **P < 0.01; 
***P < 0.001
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single-positive for HO-1 and Nrf2, respectively. Similar 
to Nrf2, some HO-1-positive cells were identified as mac-
rophages or astrocytes as well (Fig. 4j).
Neuronal expression of Nrf2 and HO‑1 is minor even 
in highly active gray matter lesions
Global Nrf2 expression was higher in the cortex com-
pared to white matter of control and MS cases (Fig. 4a), 
however, this higher expression was mainly due to a dif-
fuse cytoplasmic immunoreactivity in the neuropil. Even in 
controls, Nrf2 was already detectable in the cytoplasm of 
glial cells and neurons (Fig. 4c–f) and the expression lev-
els were highly variable between cases. A similar variabil-
ity of Nrf2 expression in the normal-appearing cortex was 
also seen in MS patients and we did not find increased neu-
ronal reactivity between MS and control cases (Fig. 5). In 
some MS and control patients, a subset of neurons showed 
an intense immunoreactivity and Nrf2 accumulation in the 
nucleus (Figs. 4c, d, 5). Such neurons showed condensed 
and hyperchromatic nuclei and eosinophilic cytoplasm, 
reminiscent of acute hypoxic damage. In active demyeli-
nating cortical lesions, strong Nrf2 immunoreactivity was 
present in oligodendrocytes and occasionally in astrocytes 
(Fig. 4h). Nrf2 reactivity within neurons was similarly low 
as in the cortex of normal controls and the normal-appear-
ing MS cortex, even in highly inflammatory cortical lesions 
with extensive NADPH oxidase expression in microglia, 
massive accumulation of oxidized lipids in the neuronal 
cytoplasm and signs of neuronal degeneration, despite high 
expression of Nrf2 in adjacent cells with oligodendrocyte 
morphology (Fig. 4h, i). A similar pattern of expression 
was seen in sections stained for HO-1. In contrast to the 
white matter, a weak diffuse reactivity for HO-1 was pre-
sent in the cytoplasm of neurons and astrocytes (Fig. 4b, 
j, k) in the control and MS cortex. Strong HO-1 reactivity 
was mainly seen in oligodendrocytes (Fig. 4k). Dystrophic 
or transected axons with disturbed axonal transport did not 
contain HO-1, despite the massive accumulation of other 
neuronal proteins such as amyloid precursor protein. These 
data suggest that in contrast to oligodendrocytes, Nrf2 
induction in neurons in response to oxidative injury in MS 
lesions was sparse.
These data are in line with the results obtained by gene 
expression analysis using whole-genome microarrays 
(Fig. 3). Only few Nrf2-responsive genes were up-regu-
lated in active cortical lesions in comparison to control cor-
tex, while the majority were unchanged or down-regulated. 
Furthermore, a separate analysis of case MS10 presenting 
with extensive inflammation, active demyelination and 
Fig. 3  Expression of Nrf2-responsive genes in white matter and cor-
tical MS lesions. The heat maps show color-coded fold changes of 
Nrf2-responsive genes in the periplaque white matter (“PP”), initial 
(prephagocytic) lesions (“I”) and active demyelinating lesions (“A”) 
as well as in active cortical lesions of all evaluated MS cases (“All”) 
or of the single case MS15 (“MS15”). Transcriptional changes were 
calculated by comparing the mean expression values of the different 
white and gray matter areas with the mean expression values of nor-
mal white matter or normal gray matter from control cases, respec-
tively. a Group 1 represents Nrf2-responsive genes that show a low 
basal expression in the NWM of controls, but were up-regulated in 
the zones of initial demyelination, while their expression in general 
was lower in the NAWM and the demyelinated part of the active 
lesion. b Group 2 consists of genes, which are expressed in high 
levels in the NWM of controls. Half of the genes within the second 
groups show an increased expression in the area of initial demyelina-
tion, while a lower fraction was down-regulated in the same lesion 
area. In contrast, no lesion activity-associated pattern of gene expres-
sion was seen in the cortex. PP periplaque white matter, I initial (pre-
phagocytic) lesion, A active demyelinating lesion
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oxidative injury did not reveal more prominent up-regula-
tion of the respective genes in comparison with the other 
cortical MS cases presenting with low demyelinating activ-
ity and a lower extent of oxidative injury.
Fumarate treatment of PML patients was not 
associated with increased Nrf2 reactivity in neurons
The effect of fumarate treatment in lesions was investigated 
in biopsies of a patient with multiple sclerosis and in 3 cases 
with PML, as previously described in Metz et al. [31]. In 
comparison to controls, this study showed a sixfold increase 
of cells with nuclear Nrf2 reactivity (mainly astrocytes) in 
the inactive MS lesion as well as in the PML lesions, but 
Nrf2 expression in the cortex has not been analyzed. We 
thus focused in the present study on neuronal Nrf2 expres-
sion in the normal appearing and not PML-affected cer-
ebral cortex included in the biopsy tissue of the same PML 
cases. Fumarate treatment did not lead to an up-regulation 
of Nrf2 in cortical neurons (Fig. 5). Instead, the number of 
Nrf2-positive neurons was in the range of untreated PML 
patients, MS patients and control subjects. Similar to control 
and MS cases, a variable proportion of neurons contained 
cytoplasmic and some nuclear reactivity. Strong nuclear 
reactivity was seen mainly in neurons with alterations of 
acute hypoxic injury such as condensed and hyperchromatic 
nuclei and eosinophilic cytoplasm (Figs. 4d, 5).
Nrf2 expression in the white matter is increased 
by concomitant presence of brain hypoxia or systemic 
inflammation
In white matter microinfarcts, which are occasionally pre-
sent within the CNS of control patients without neurologi-
cal disease, we observed an increased Nrf2 expression in 
oligodendrocytes and sparse astrocytes (Fig. 2d). Thus, we 
included only MS cases without any concomitant neuro-
pathological alterations in our MS samples. Further analy-
ses showed that in control patients, who died under septic 
conditions but did not reveal any inflammatory alterations 
in the brain or spinal cord, increased numbers of Nrf2-pos-
itive cells were found within the NWM (Fig. 2d). For this 
reason, MS patients (n = 4) who died in the course of sys-
temic inflammatory diseases (e.g., pneumonia) were sepa-
rately analyzed regarding Nrf2 expression in the NAWM 
and lesions. These patients showed the same lesion-asso-
ciated patterns of Nrf2 expression compared with the 
other MS patients (data not shown). Furthermore, exclud-
ing these patients from the statistical analyses provided in 
Fig. 2 revealed only minor changes in the median values 
of the respective groups and had no influence on statisti-
cal significance levels (data not shown). These data indi-
cate that concomitant local pathology as well as systemic 
inflammation may result in increased oxidative stress and 
Nrf2 expression within the brain white matter, but that 
these factors had no major influence on the Nrf2 expression 
patterns related to MS pathology.
Discussion
The concept of neuroprotective treatment of multiple scle-
rosis patients with fumarates is based on their anti-inflam-
matory actions [38], mediated for instance by inhibition 
of microglia activation [35] and on their induction of the 
transcription factor Nrf2 and of endogenous downstream 
anti-oxidant defense mechanisms [28, 37]. This treatment 
paradigm is supported by the observation that oxidative 
injury is a major factor involved in demyelination and neu-
rodegeneration in the CNS of MS patients.
The potential anti-oxidative protective effect of fuma-
rates may depend on the pre-existent expression levels of 
Nrf2 in cells or tissues. Fumarates induce Nrf2 and are 
neuroprotective in conditions of no or low basic expres-
sion of Nrf2, such as during EAE [28]. However, in condi-
tions of pre-existing profound oxidative stress, high basic 
expression of Nrf2 can be expected, which may not be fur-
ther increased by fumarate treatment. Additional fumarate-
induced cells stress in oligodendrocytes or neurons already 
Fig. 4  Nrf2 and HO1 expression in the cortex of MS patients and 
controls determined by qualitative immunohistochemistry. Low-
magnification figure showing Nrf2 (a) and HO1 (b) expression in the 
cortex (left-hand side) and adjacent white matter (right-hand side). 
In cortical areas derived from both, controls (a; case CO 1) and MS 
patients (b; case MS 22), a higher cellular and diffuse expression of 
these antigens in comparison with the adjacent white matter is appar-
ent. Examples of cellular expression of Nrf2 in the cortex; c neuronal 
cytoplasmic and nuclear expression in MS cortex; (d; case MS 1): 
neuron with strong cytoplasmic and nuclear Nrf2 reactivity in the 
cortex of an MS patient (case CO 8); e Nrf2 expression in a reactive 
astrocyte in a cortical lesions of an MS patient (case MS 8); f Nrf2 
expression in inflammatory macrophages in a perivascular cuff in an 
active cortical MS lesion (case MS 10); g Nrf2 expression in small 
oligodendrocyte-like cells in the cortex of a control patient (case MS 
20). h, i Nrf2 expression in a highly active cortical MS lesions is pre-
dominantly seen in oligodendrocytes (h), despite extensive NADPH 
oxidase (p22phox subunit) expression in microglia (blue) and exten-
sive accumulation of oxidized phospholipids (E06; brown) in corti-
cal neurons (case MS 10). HO-1 expression in the MS cortex is vari-
able between cases and regions and can be seen in astrocytes (j; case 
MS 22), in oligodendrocytes (k, MS 22) and in neurons (l; MS 22). 
m, n Nrf2 expression in cortical neurons in two patients with PML 
under fumarate treatment showing either single positive neurons (m; 
case PML Fumarate 1) or small clusters of immunoreactive neurons, 
mainly consistent of shrunken cells with condensed nuclei (case 
PML Fumarate 2). Scale bars a, b = 100 μm; c–j and l–n = 30 μm; 
k = 20 μm
◂
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exposed to severe oxidative injury might even increase 
demyelination or neurodegeneration. Further induction of 
Nrf2 in cells, which already express this protein at high lev-
els, may propagate cell death by interacting with another 
promotor element through the induction of KLF-9 [46]. 
Thus, anti-oxidant effects of fumarates may differ pro-
foundly depending on the degree of oxidative injury and 
pre-existing expression levels of Nrf2 in the tissue.
For these reasons, it is important to know in detail the 
extent and patterns of Nrf2 expression in MS patients at 
different disease stages and in different lesion types. So 
far, only two studies have addressed this question and con-
cluded that its low expression may be insufficient to protect 
the tissue against oxidative injury. In our present study, we 
found very prominent Nrf2 expression predominantly in 
oligodendrocytes at sites of initial demyelination in active 
MS lesions. Within these cells, Nrf2 appeared to be func-
tionally active, as indicated by the expression of HO-1 
in the same cells and the selective up-regulation of other 
Nrf2-responsive genes in microdissected lesion areas with 
initial stages of demyelination and tissue injury. As in our 
study, presence of HO-1 in oligodendrocytes has been pre-
viously described in active MS lesions [40]. Excessive Nrf2 
expression was seen in cells with signs of cell degeneration, 
such as the loss of cytoplasmic marker proteins and nuclear 
DNA fragmentation. Furthermore, the liberation of AIF 
from mitochondrial stores into the cytoplasm and nucleus, 
as seen in cells with excessive Nrf2 expression, has been 
already described as a major pathway for oxidative cell 
death in MS lesions [15, 44]. High Nrf2 expression was 
present in active lesions of acute and relapsing MS as well 
as in slowly expanding lesions in progressive MS. Nrf2-
positive astrocytes and macrophages were seen mainly in 
later stages of active lesions characterized by complete 
demyelination and profound oligodendrocyte loss. Such a 
pattern of Nrf2 immunoreactivity has been reported previ-
ously by van Horssen et al. [41]. In contrast to this report, 
we also included in our study patients with acute MS and 
highly active lesions and we also used very stringent cri-
teria for identification of lesional activity in patients with 
progressive MS based on the presence of early myelin deg-
radation products in macrophages. Nrf2 expression in MS 
is fundamentally different from that seen in EAE, where 
it is sparse or absent even in highly active lesions, but is 
induced in oligodendrocytes, astrocytes, macrophages and 
neurons after fumarate treatment [28].
So far, we convincingly found Nrf2 in mature oligoden-
drocytes in active MS lesions, but we cannot draw conclu-
sions on its expression in oligodendrocyte progenitor cells 
(OPCs). Although a variety of markers for OPCs are cur-
rently available, none of them work with convincing reli-
ability in archival autopsy tissue with variable post mortem 
autolysis time and formaldehyde fixation time.
Expression of Nrf2 in neurons has been described in con-
trol patients and in various neurodegenerative diseases, but 
it was concluded that its expression may be insufficient to 
prevent neuronal degeneration [36]. In our study, the nuclear 
Nrf2 reactivity in neurons in MS lesions was low or absent, 
even in gray matter lesions with extensive acute oxidative 
injury. Only exceptionally, neurons with morphological fea-
tures of acute (terminal) hypoxic injury revealed prominent 
Nrf2 up-regulation and nuclear translocation. Interestingly, 
Fig. 5  Nrf2 expression in cortical neurons. Based on the level of 
Nrf2 immunoreactivity (cytoplasmic and nuclear), we distinguished 
between two types of Nrf2-positive neurons: neurons with weak 
and neurons with strong Nrf2 expression. Examples are shown in 
(b) and labeled as weak (W) or strong (S). a Grouped according to 
Nrf2 immunoreactivity (weak or strong), a quantitative comparison 
of Nrf2-positive cortical neurons revealed no significant differences 
between control, MS, PML and fumarate-treated PML cases within 
each group. In addition to the actual data points (open and closed cir-
cles), the median of each data set is indicated by a gray bar. Scale 
bar 50 µm
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within the same sections and lesion areas, oligodendrocytes 
with abundant Nrf2 expression were located in close vicin-
ity to Nrf2-negative neurons. Thus, the lack of Nrf2 expres-
sion in neurons is not due to different lesion environments 
between gray and white matter, but seems to reflect an 
intrinsic difference in the reaction to inflammation, demy-
elinating and oxidative stress between neurons and oligo-
dendrocytes. The low induction of Nrf2 in cortical neurons 
was also reflected by the lack of induction of most Nrf2-
responsive anti-oxidant molecules and may also be related 
to the down-regulated expression of another transcription 
factor (peroxisome proliferator-activated receptor gamma, 
coactivator 1 alpha, PGC-1α, encoded by the PPARGC1A 
gene), which regulates mitochondrial anti-oxidant mecha-
nisms [45]. In addition, it has been recently shown that Nrf2 
expression is repressed in neurons in the adult nervous sys-
tem by epigenetic inactivation of its promotor [3]. Profound 
induction of Nrf2 has been seen in neurons in vitro [37] and 
in vivo in EAE animals treated with fumarates [28] and pro-
tected neurons against oxidative injury [37]. However, as in 
MS patients, in PML patients treated with fumarate we did 
not observe an increase of nuclear Nrf2 reactivity in cortical 
neurons, despite increased nuclear immunoreactivity within 
the white matter lesions of the same patients [31]. This may 
be of major importance for the interpretation of treatment 
effects in patients with progressive MS, since gray matter 
damage appears to play a key role in disability progression 
[7, 13].
A limitation of our study is that pathology does not pro-
vide direct information on the temporal pattern of Nrf2 
expression. Thus, induction of Nrf2 expression by fuma-
rates in oligodendrocytes before new lesions are formed 
may be protective, while its further stimulation in active 
lesions might have no or even opposite effects. In addition, 
up-regulation of anti-oxidant defense molecules in astro-
cyte may indirectly exert neuroprotective effects in adjacent 
cells such as neurons [33]. This view is further supported 
by previous studies, which showed that anti-oxidant mol-
ecules such as NAD(P)H:quinone oxidoreductase 1, thiore-
doxin-2, or thioredoxin reductase are mainly expressed in 
astrocytes, while these anti-oxidant defense mechanisms 
are less effective in neurons [6, 12, 33, 42]. Overall, our 
study provides further evidence for an important role of 
oxidative stress as a mechanism of demyelination and neu-
rodegeneration in MS and for extensive up-regulation of 
anti-oxidant defense molecules at least in active white mat-
ter lesions.
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